Published online Jun 14, 2013. doi: 10.3748/wjg.v19.i22.3371
Revised: May 2, 2013
Accepted: May 9, 2013
Published online: June 14, 2013
Core tip: The use of intraoperative blood salvage autotransfusion (IBSA) in hepatocellular carcinoma (HCC) patients undergoing liver transplantation is controversial as it may reinfuse salvaged blood contaminated by tumor cells. In this article, we reviewed the relevant literature and tried to address the critical questions about IBSA. The available data indicate that IBSA is safe in liver transplantation for HCC, but randomized, controlled and prospective trials are urgently required to clarify the uncertainty.